OXiGENE has launched its newly designed website. The site provides access to the company’s clinical research, investor information and a video demonstrating how OXiGENE’s lead vascular targeting agent, Combretastatin A4 Prodrug, inhibits blood flow within tumor cells.
All corporate materials will include the newly trademarked tagline The Vascular Targeting Company, reflecting OXiGENE’s product and technology focus.
Our new website conveys the growth and development of our vascular targeting technology and our focus on being first to market with a commercial drug, said Dr Bjorn Nordenvall, OXiGENE’s CEO, in a company release.
It reflects not only our successful completion of three Phase I clinical trials of Combretastatin A4 Prodrug, (CA4P), but our objectives for next-generation products including the recently announced Oxi-4503. CA4P is only the initial step in our core strategy to develop a family of vascular targeting agents that attack the blood vessels feeding tumor cells. Our goal is to have vascular targeting become synonymous with front-line disease treatment, and to have OXiGENE become synonymous with vascular targeting, continued Dr Nordenvall.